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Abstract Using insulin-like growth factor-binding protein-2
(IGFBP-2) transgenic mice (D mice) as a model of elevated
IGFBP-2 expression, which is often found in unphysiological
conditions, we found association of IGFBP-2 to puri¢ed plasma
membranes of many organs. To determine whether the RGD
(Arg-Gly-Asp) motif of IGFBP-2 mediates cell surface binding
in vivo, we mutated the RGD motif of IGFBP-2 into an RGE
(Arg-Gly-Glu) sequence and produced transgenic mice (E mice)
which express elevated amounts of mutated IGFBP-2. Our data
demonstrate that in vivo IGFBP-2 cell surface association is not
dependent on the RGD motif and that mutation of this sequence
does not alter growth inhibitory e¡ects of IGFBP-2. - 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The insulin-like growth factor-binding proteins (IGFBPs)
present in di¡erent biological £uids can also be found in as-
sociation with cell surfaces which they can bind via heparin-
binding domains [1] or RGD motifs [2]. The presence of these
binding sites for the insulin-like growth factors (IGFs) on the
cell surface or in the extracellular matrix clearly points to a
role for the IGFBPs in controlling IGF-I bioavailability in the
pericellular space, e.g. by regulating receptor access of IGF-I
[3]. As a consequence of cell surface association reduced af-
¢nity for the IGFs has been described for IGFBP-2 [4], -3
[5,6] and -5 [7]. In addition, IGF-independent actions of
IGFBPs are implicated with the feature of membrane associ-
ation [8^10]. IGFBP-2 possesses a putative heparin-binding
domain (HBD) [11], possibly similar to that present in
IGFBP-3 and -5 [1,12,13]. Additionally, an RGD motif exists
in IGFBP-2 which is also present in IGFBP-1 and is involved
in binding to K5L1 integrin [8]. IGFBP-2 cell surface associa-
tion has been reported in a number of tissues and cells [4,14^
16]. However, the relative contributions of the HBD or the
RGD domain for membrane association are unknown. A
function of the RGD motif present in IGFBP-2 in vivo re-
mains to be established. To identify target tissues of IGFBP-2,
we asked if IGFBP-2 binds to plasma membranes from di¡er-
ent tissues in IGFBP-2 transgenic mice (D mice). The poten-
tial relevance of the RGD motif for cell surface binding was
characterized in a transgenic mouse model (E mice) overex-
pressing mutant IGFBP-2 which lacks the RGD motif.
2. Materials and methods
2.1. Generation of two point mutations leading to an amino acid
exchange
The wild-type mouse IGFBP-2 containing expression vector CMV-
int-IGFBP-2 [17] was mutated by overlap extension PCR. Two par-
tially overlapping PCR products were generated by use of the mouse
IGFBP-2 cDNA sequence and primer 1s (C CAC CAT CCG CGG
AGA ACC CGA GTG C) and primer 1as (CTC TCT AAC AGA
AGC AAG G) as well as primer 2s (GAC GCT ACG CTG CTA
TCC CAA) and primer 2as (GCA CTC GGG TTC TCC GCG GAT
GGT GG). The resulting PCR product was KpnI/PstI-digested and
cloned into the KpnI/PstI-digested puri¢ed expression vector back-
bone void of the cDNA sequence. The generated expression vector
coded for mouse IGFBP-2 containing an RGE instead of an RGD
sequence (Fig. 1A). In parallel, a second point mutation was intro-
duced to generate a restriction site which allowed for simpli¢ed
screening of the mutation via SacII digestion. The mutation was veri-
¢ed by sequence analysis. The mutated IGFBP-2 di¡ers by only one
methylene group compared to wild-type IGFBP-2, while the net
charge is identical in both proteins.
2.2. Generation of transgenic mice
Transgenic mice were generated by microinjection of the 3.2-kb
SpeI/XhoI fragment from the expression vector pCMV-int-mIGFBP-
2 into pronuclei of fertilized eggs from superovulated donors
(B6D2F1UB6D2F1). The injected embryos were transferred to pseu-
dopregnant female mice (CD-0). Genomic DNA from tail tips of 3-
week-old o¡spring was isolated using the Puregene genomic DNA
puri¢cation system (Biozym, Hess. Oldendorf, Germany). Transgenic
o¡spring of two founder mice were produced by backcrossing with
C57BL/6 mice and identi¢ed by PCR analysis (CMV-speci¢c sense
primer: 5P-GTG TAC GGT GGG AGG TC-3P ; IGFBP-2-speci¢c
antisense primer: 5P-TCG GCA GCA TGT TGG CTT GT-3P) ac-
cording to standard protocols from 100 ng of genomic DNA from tail
tips.
2.3. Serum measurements of IGF-I, -II and IGFBP-2
Radioimmunoassays were performed as described before [17].
2.4. Analysis of body and organ growth in E mice
Mice were weighed to the nearest 0.1 g. Transgenic E mice and
littermate controls of di¡erent ages were anesthetized with ether and
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killed by bleeding from the retro-orbital sinus. The weights of body,
carcass and pancreas which showed the most prominent reductions in
D mice were recorded. For the analysis, pancreas was removed, blot-
ted dry and weighed to the nearest mg. Carcasses were weighed after
removal of the organs without skin, head and tail. Pancreas and
carcass weight data were divided by the respective body weights to
calculate relative weights. Body and organ weight data of transgenic
mice were expressed as percentage of the mean calculated for sex- and
age-matched non-transgenic littermates. Di¡erences were statistically
evaluated using the unpaired Student’s t-test.
2.5. Analysis of IGFBP mRNA expression and veri¢cation of the
introduced mutation
Tissues from D and E mice were homogenized in guanidinium
thiocyanate and RNA was pelleted in 5.7 M CsCl by ultracentrifuga-
tion. 2 Wg of total RNA was DNase I-digested and reverse-transcribed
according to standard procedures. A PCR product was ampli¢ed us-
ing £anking primers (sense: 5P-GAG TTG CTG GTG TGT GAA
CC-3P, antisense: 5P-CTC TCT AAC AGA AGC AAG G-3P). After
electrophoretic puri¢cation the PCR product was digested with SacII.
The SacII restriction site had been introduced during the mutagenesis
and is absent in wild-type IGFBP-2.
2.6. Preparation of tissue extracts
Frozen tissue samples were thawed and homogenized in extraction
bu¡er (10 mM Na2HPO4, pH 7.0; 0.2% (w/v) sodium dodecyl sulfate
(SDS); 10% (w/v) glycerin) using a cell homogenizer (Art, Mu«hlheim,
Germany). The tissue lysates were centrifuged for 5 min at 21 000Ug
at 4‡C and protein concentrations were determined.
2.7. Membrane preparation
Membranes were prepared as described before [4]. In brief, tissues
were homogenized in a lysis bu¡er (10 mM Tris, 2 mM phenylmeth-
ylsulfonyl £uoride, 1 TIU/ml of aprotinin) for 1 min at 10 000 rpm on
ice using a cell homogenizer (Art). Cell debris and nuclei were sepa-
rated by centrifugation (1000Ug, 10 min, 4‡C). The supernatant con-
taining plasma membranes and the cytosolic fraction were separated
by centrifugation for 30 min at 21 000Ug at 4‡C. The isolated plasma
membranes contained highly enriched activities of the plasma mem-
brane marker enzyme alkaline phosphatase (EC 3.1.3.1) compared to
whole tissue lysates and minimal enzyme activities of cytosolic gluta-
thione S-transferase (EC 2.5.1.18; data not shown). Thus the plasma
membrane fraction was contaminated by cytosolic components only
to a small extent.
2.8. Incubation of the membranes
Plasma membranes (10 Wg) were incubated with synthetic peptides
(100 Wg/ml) containing the RGD motif or the RGE sequence
(GRGDSP or GRGESP) or in 500 mM NaCl overnight in a rotator
at 4‡C. Membranes were centrifuged for 5 min at 21 000Ug and both
pellet and supernatant were analyzed.
2.9. Capacity of [125I]IGF-II binding
Extracts and plasma membranes from di¡erent tissues were ana-
lyzed by Western ligand blot analysis as previously described [17] to
demonstrate the molecular weight of the transgene product and its
capacity to bind human IGF-II. Fifty micrograms of protein were
boiled (5 min) and electrophoresed on a 5% stacking/12% separating
SDS^polyacrylamide gel using the Mini Protean II1 system (Bio-Rad,
Fig. 1. A: Two point mutations lead to an amino acid exchange and the generation of a SacII recognition motif (ccgcgg) used for detection of
the mutation. B: The mutated sequence is present in cDNA derived from the mesentery of E mice but not in D mice. cDNA was reverse-tran-
scribed from total RNA preparations and an IGFBP-2-speci¢c PCR product was ampli¢ed and puri¢ed by gel electrophoresis. SacII restriction
enzyme digestion resulted in partial hydrolysis of the PCR product from E but not from D mice.
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Munich, Germany). Separated proteins were transferred to a nitro-
cellulose membrane (Millipore, Eschborn, Germany). To check equal
loading, the blots were routinely stained in 0.2% Ponceau red/3%
acetic acid. The blots were blocked with 1% ¢sh gelatin and incubated
with [125I]IGF-II (106 cpm per blot). Binding proteins were visualized
and quanti¢ed on Phosphor-Imager Storm (Molecular Dynamics,
Krefeld, Germany). All incubations and washing steps were per-
formed at 4‡C.
3. Results and discussion
IGFBP-2 transgenic mice [17] were used in the present
study as a model of elevated IGFBP-2 expression found in
many unphysiological conditions [18] and to identify target
tissues binding IGFBP-2 on their cell surface. To unequivo-
cally answer the question if the RGD sequence a¡ects cellular
distribution of IGFBP-2 in vivo we generated IGFBP-2 trans-
genic mice which express high levels of mutant IGFBP-2 lack-
ing the RGD motif.
3.1. Presence of the mutation in RNA transcripts
Elevated IGFBP-2 mRNA levels and the mutation were
veri¢ed in the E mice by reverse transcription PCR from total
RNA isolated from muscle, kidney, heart and mesentery and
by digestion IGFBP-2-speci¢c PCR products using the SacII
restriction enzyme. In cDNA derived from E mice SacII di-
gestion resulted in partial hydrolysis of the 329-bp PCR prod-
uct to two fragments of 273 bp and 56 bp, whereas in D mice
the PCR product was not digested (Fig. 1B). Thus the muta-
tion was veri¢ed by analytical digestion using a restriction
enzyme in addition to sequence determination.
3.2. Serum concentrations of IGFBP-2, IGF-I and IGF-II
Serum concentrations of IGFBP-2 were signi¢cantly
(P6 0.05) increased by about 30% in E mice (795Q 172 ng/
ml) compared to non-transgenic littermates (606Q 127 ng/ml).
D mice had much higher serum IGFBP-2 concentrations
(1021Q 320 ng/ml) [17] compared to E mice. The di¡erences
of serum IGFBP-2 concentrations in the di¡erent transgenic
lines might be explained by di¡erent transgene expression due
to di¡erent genomic integration sites of the expression vectors.
Total serum levels of IGF-I and IGF-II in E mice (377Q 58
ng/ml and 28Q4 ng/ml) were similar compared to non-trans-
genic littermates (407Q 40 ng/ml and 26Q 2.5 ng/ml).
3.3. E¡ects on body and organ weights
E mice were weighed at di¡erent ages between 4 and 9
months and compared with sex- and age-matched non-trans-
genic littermates (Fig. 2). Body weight was signi¢cantly
(P6 0.001) reduced by 7% in the E mice. For carcass and
pancreas the reductions of relative weights amounted to
13% (P6 0.001) and 10% (P6 0.001), respectively, compared
to controls. The weight reductions were similar in E mice and
in D mice described earlier [17]. The carcass displayed the
strongest weight reduction in both transgenic groups, followed
by pancreas and body weight. Therefore, E mice had a similar
overall phenotype compared to D mice although both trans-
genic lines had di¡erent serum IGFBP-2 levels. This ¢nding
suggests that a relatively small increase in serum IGFBP-2
levels is su⁄cient for a limited growth inhibitory e¡ect or
that tissue levels of IGFBP-2 are the more relevant factor
for growth inhibition by elevated IGFBP-2. The latter possi-
bility is in line with the revised somatomedin hypothesis which
points to important local e¡ects of the IGF system for organ
growth [19].
3.4. Tissue expression
Transgene expression of RGE-IGFBP-2 was analyzed by
Western ligand blotting in di¡erent organs and compared
with transgene expression of RGD-IGFBP-2 transgenic
mice. In both transgenic groups, a strong band at 32 kDa
was found in muscle, spleen, kidneys, brain, heart, pancreas,
mesentery and stomach. No obvious di¡erences in tissue ex-
pression were observed between both transgenic groups (Fig.
Fig. 2. Weight reductions in E mice. Weights were recorded from
animals of di¡erent ages and expressed in percent of their respective
sex- and age-matched non-transgenic littermates. The weights of car-
cass and pancreas were divided by the respective body weights and
thus represent relative weights (n=12; *P6 0.05). For direct com-
parison the weight reductions present in D mice as shown previ-
ously [19] have been included in the ¢gure.
Fig. 3. Transgene expression in di¡erent tissues from D and E mice
and non-transgenic controls (C). Tissue lysates were prepared as de-
scribed in Section 2 and the presence of IGFBPs was analyzed by
Western ligand blotting using [125I]IGF-II.
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3). IGFBP-2 protein could be detected in liver tissue from
both IGFBP-2 transgenic groups only after long exposure of
the membrane. In tissues from non-transgenic littermates only
a relatively faint band of similar molecular weight was
present. It can thus be concluded that the strong signals
present in both transgenic groups are due to transgenic
IGFBP-2 and not to endogenous IGFBP-2 expression. There-
fore, the RGD sequence is not necessary for binding of IGFs.
This conclusion has been drawn before from structural studies
of IGFBP-1 [20].
3.5. Membrane association of IGFBP-2
Having demonstrated transgene expression in di¡erent tis-
sues from both transgenic groups we investigated by Western
ligand blotting if IGFBP-2 is associated with plasma mem-
branes isolated from the respective tissues. First we aimed
to demonstrate the speci¢city of IGFBP-2 binding to the plas-
ma membranes. Thus, we tested the e¡ects of di¡erent agents
on membrane association of IGFBP-2. Synthetic peptides
(GRGDSP or GRGDESP) had no e¡ects on binding of
IGFBP-2 to puri¢ed membranes (Fig. 4). By contrast, NaCl
at high concentration was able to dissociate IGFBP-2 mole-
cules from their binding sites and dissociated IGFBP-2 was
found in the supernatant, demonstrating the absence of cyto-
solic contamination and the speci¢city of cell surface associa-
tion. However, the use of RGD-containing peptides might
produce biased results since the three-dimensional structure
of the RGD sequence is dependent on the £anking sequences
[21,22] and may be di¡erent in peptides or proteins. We thus
investigated the cell surface association of mutated IGFBP-2
lacking the RGD motif. Under non-reducing conditions at 32
kDa a band was present in membrane preparations from all
tissues in both transgenic groups which was able to bind
[125I]IGF-II (Fig. 5). We conclude that the strong signals
present in E and D mice are due to transgenic IGFBP-2. Since
both wild-type and mutant IGFBP-2 was cell surface-associ-
ated we conclude that the RGD motif is not necessary for cell
surface association in the tissues examined. However, condi-
tional generation of high-a⁄nity integrin-binding sites by ei-
ther enhanced integrin gene expression [23] or conformational
changes [24] has been described. It thus cannot be excluded by
the present study that IGFBP-2 under certain, e.g. malignant,
conditions could make use of its RGD domain and activate
integrin-dependent signal cascades as demonstrated for
IGFBP-1 [8], while in the absence of the RGD domain integ-
rin-dependent signal cascades might remain silent.
In mouse IGFBP-2 a putative HBD is resident on the C-
terminal domain (amino acids 195^200; PKKLRP). This pu-
Fig. 4. IGFBP-2 is dissociated by high concentrations of NaCl but not by synthetic RGD- or RGE-containing peptides. Puri¢ed plasma mem-
branes from D mice were incubated with or without di¡erent agents to demonstrate speci¢city of cell surface association and the absence of
soluble cytosolic contamination.
Fig. 5. Association of IGFBP-2 to puri¢ed plasma membranes from
di¡erent tissues of D and E mice and non-transgenic controls (C).
Plasma membranes were isolated from various tissues as described
in Section 2 and the presence of IGFBPs was analyzed by Western
ligand blotting using [125I]IGF-II.
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tative sequence motif was discussed as being involved in cell
surface association in several species [11]. The ¢ndings that
this sequence motif is absent in zebra¢sh and IGFBP-2 is not
cell surface-associated in that species gives at least some evi-
dence for an involvement of the HBD with membrane asso-
ciation [11]. In vitro it has been shown that IGFBP-2 binds to
heparin or the extracellular matrix [25] and cell surface pro-
teoglycans have been characterized and shown to bind
IGFBP-2 in olfactory bulbs from the rat brain [4]. Since pro-
teoglycans are widely distributed [26] and we demonstrate the
presence of IGFBP-2 on the cell surface in all tissues inves-
tigated, it might be assumed that IGFBP-2 binds to tissues in
a ubiquitous manner. Cell surface association might result in
high local tissue levels of IGFBP-2 but not in adequate serum
concentrations. The ¢nding that local IGFBP-2 concentra-
tions and weight reductions were similar in both transgenic
groups while the serum concentrations were di¡erent indicates
a more important role of local versus systemic IGFBP-2.
In conclusion, our data clearly demonstrate that IGFBP-2
binds to the cell surface in many tissues and that the RGD
motif present in IGFBP-2 is not necessary for cell surface
association or growth inhibitory e¡ects of IGFBP-2 in trans-
genic mice. Our results suggest an important role of IGFBP-2
in the pericellular compartment.
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